Common genetic mutations in adult GBM frequently targeted by immunotherapy include the epidermal growth factor receptor variant III (EGFRvIII) mutation and the isocitrate dehydrogenase (IDH1) R132H mutation, while targets in pediatric gliomas include a conserved missense mutation in histone H3 from lysine (K) to methionine (M) at position 27 (H3 K27M mutation) [34–36]. This evidence concerns the gene IDH1 and glioma.